课题基金 / 基金详情

Novel targets for HIV-1: Tat-TAR interactions

Novel targets for HIV-1: Tat-TAR interactions
HIV-1 的新靶标:Tat-TAR 相互作用
批准号:
6405888
负责人:
Robert Rando
金额:
$14.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-10 至 2002-03-31

项目摘要

项目成果

Robert Rando的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):人类免疫缺陷病毒
英文摘要
DESCRIPTION (Provided by the applicant): The human immunodeficiency virus type-i (HIV-i) is a complex retrovirus that encodes six regulatory proteins, including Tat. The Tat protein is a potent transcriptional activator of the HIV-1 long terminal repeat promoter element. A regulatory element between +1 and +60 in the HIV-1`long terminal repeat which is capable of forming a stable stem-loop structure, designated TAR, is critical for Tat function. In the absence of Tat, RNA polymerase II (pol II) terminates transcription prematurely. Tat-TAR interactions help convert pol II interactions with the RNA template into efficiently produced full-length viral transcripts. We have recently demonstrated that combinatorial libraries composed of tripeptides contained molecules that not only bound to TAR but also inhibited Tat interaction with Tar and subsequent LTR directed transcription was reduced in cell culture. The goal of the proposed research is the discovery of low molecular weight non-peptide compounds that inhibit HIV replication by binding to the TAR RNA element. The success of this research would open the door to new opportunities in the discovery of drugs which bind to discrete RNA structures with possible applications for diseases such as cancer and aids. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTIVE ANTIHIV GUANOSINE/THYMIDINE OLIGONUCLEOTIDES
  • 批准号:
    2074045
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    1995
  • 负责人:
    Robert Rando
  • 依托单位:
ANTI-HCMV ACTIVITY OF TRIPLE HELIX-FORMING OLIGOS
SMALL INSTRUMENTATION PROGRAM
海外基金